BiotechTube

Cushing's syndrome confirmation

Pre-clinicalTerminated
0 watching 0 views this week💤 Quiet
18
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cushing's Syndrome

Conditions

Cushing's Syndrome

Trial Timeline

Feb 1, 2009 → —

NCT ID
NCT00796783

About Cushing's syndrome confirmation

Cushing's syndrome confirmation is a pre-clinical stage product being developed by Corcept Therapeutics for Cushing's Syndrome. The current trial status is terminated. This product is registered under clinical trial identifier NCT00796783. Target conditions include Cushing's Syndrome.

Hype Score Breakdown

Clinical
5
Activity
2
Company
5
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT00796783Pre-clinicalTerminated

Competing Products

18 competing products in Cushing's Syndrome

See all competitors
ProductCompanyStageHype Score
AZD4017 and prednisolone + Placebo Oral Tablet and prednisoloneAstraZenecaPhase 2
52
pasireotide LAR + SOM230 LAR 30 mg + SOM230 LAR 10 mgNovartisPhase 3
77
Pasireotide sub-cutaneousNovartisPhase 3
77
osilodrostat + osilodrostat PlaceboNovartisPhase 3
77
OsilodrostatNovartisPhase 2
52
PasireotideNovartisPhase 3
77
Pasireotide s.c. + Sitagliptin + Liraglutide + Insulin + Pasireotide LAR + MetforminNovartisApproved
85
SOM230 s.c.NovartisPhase 2
52
Lu AG13909LundbeckPhase 2
49
OsilodrostatRecordatiPre-clinical
20
Pasireotide + Cabergoline + Pasireotide LARRecordatiApproved
82
osilodrostatRecordatiPhase 2
49
OsilodrostatRecordatiPre-clinical
20
mifepristoneCorcept TherapeuticsPhase 3
72
CORT125134Corcept TherapeuticsPhase 2
47
MifepristoneCorcept TherapeuticsPhase 3
72
mifepristoneCorcept TherapeuticsPhase 3
72
mifepristoneCorcept TherapeuticsPhase 3
72

Other Products from Corcept Therapeutics

Mifepristone 300 MG [Korlym] + Placebo for mifepristoneApproved
80
mifepristonePhase 3
72
mifepristone + placeboPhase 3
72
RelacorilantPhase 3
72
Mifepristone + placeboPhase 3
72